drugset / Trial / NCT01429675

Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers

NCT01429675

Phase 1 Completed 105 enrolled Alvogen Korea
RandomizedCrossoverOpen-label

Summary

The purpose of this study is compare the pharmacokinetic characteristics of DP-R206 (150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) and Bonviva (150mg Ibandronate, qd) after oral administration in healthy adult volunteers.

Timeline

Start
2011-08
Primary completion
2012-02
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibandronate Other / unclassified 150 mg Oral

Indications

No indication recorded.